Drugs / Synthetic Conjugated estrogens, B
Synthetic Conjugated estrogens, B
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00196378 | Nov 2004 → Feb 2006 | — | Duramed Research | Completed | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Synthetic Conjugated estrogens, B | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00196378 ↗ |
| Known as | CE-10 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201467 ↗ |
| Known as | Enjuvia | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201467 ↗ |
| Known as | Estrogens, conjugated synthetic b | ChEMBL registry synonym — accepted as the source's own label CHEMBL1201467 ↗ |
| Known as | SCE-B | “OBJECTIVE: To evaluate the safety and efficacy of synthetic conjugated estrogens B (SCE-B; 0.3 mg/d) for 12 weeks in the treatment of vulvovaginal atrophy in symptomatic,...” PMID 18053998 ↗ Dec 2007 |
| Route | Oral | “Daily oral administration, in a randomized, placebo-controlled setting, of SCE-B (0.3 mg) or of placebo for 12 weeks.” PMID 18053998 ↗ Dec 2007 |